Chronic melatonin treatment and the hypothalamo-pituitary-adrenal axis in the rat: attenuation of the secretory response to stress and effects on hypothalamic neuropeptide content and release.
about
The transcription factor E4BP4 regulates the production of IL-10 and IL-13 in CD4+ T cellsMolecular mechanisms that control the expression and activity of Bcl-6 in TH1 cells to regulate flexibility with a TFH-like gene profileMetabolic Impact of Light Phase-Restricted Fructose Consumption Is Linked to Changes in Hypothalamic AMPK Phosphorylation and Melatonin Production in Rats.The mouse and human Fli1 genes are similarly regulated by Ets factors in T cells.Effects of Melatonin on Adrenal Cortical Functions of Indian Goats under Thermal Stress.GATA3 cooperates with PARP1 to regulate CCND1 transcription through modulating histone H1 incorporation.Control of the differentiation of regulatory T cells and T(H)17 cells by the DNA-binding inhibitor Id3.Neuroimmune endocrine effects of antidepressantsMelatonin does not inhibit hypothalamic-pituitary-adrenal activity in waking young men.Group 2 innate lymphoid cells license dendritic cells to potentiate memory TH2 cell responses.Nuclear matrix binding protein SMAR1 regulates T-cell differentiation and allergic airway diseaseCytokine expression by invariant natural killer T cells is tightly regulated throughout development and settings of type-2 inflammation.Cytokines of the γ(c) family control CD4+ T cell differentiation and function.Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma.Central Interleukin-1β Suppresses the Nocturnal Secretion of MelatoninGATA-3 controls the maintenance and proliferation of T cells downstream of TCR and cytokine signaling.BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis.Nicotinic acetylcholine receptor agonist attenuates ILC2-dependent airway hyperreactivity.Interleukin-17 and its expanding biological functions.Intrathymic programming of effector fates in three molecularly distinct γδ T cell subtypesThe IL-23-IL-17 axis in inflammatory arthritis.Synthetic melatoninergic ligands: achievements and prospects.T-bet in the spot light: roles in distinct T-cell fate determination.The transcription factor musculin promotes the unidirectional development of peripheral Treg cells by suppressing the TH2 transcriptional programConditional IL-4/IL-13-deficient mice reveal a critical role of innate immune cells for protective immunity against gastrointestinal helminths.Nucleic acid sensing by T cells initiates Th2 cell differentiation.The transcription factor Sox4 is a downstream target of signaling by the cytokine TGF-β and suppresses T(H)2 differentiation.Pineal-adrenal-immune system relationship under thermal stress: effect on physiological, endocrine, and non-specific immune response in goats.FTY720, a sphingosine 1-phosphate receptor modulator, inhibits CD1d-restricted NKT cells by suppressing cytokine production but not migration.The CD4+CD26- T-cell population in classical Hodgkin's lymphoma displays a distinctive regulatory T-cell profile.Highly self-reactive naive CD4 T cells are prone to differentiate into regulatory T cells.A novel immunodeficiency disorder characterized by genetic amplification of interleukin 25.T helper type 2 differentiation and intracellular trafficking of the interleukin 4 receptor-alpha subunit controlled by the Rac activator Dock2.TGF-β-mediated airway tolerance to allergens induced by peptide-based immunomodulatory mucosal vaccination.A T-cell-specific CD154 transcriptional enhancer located just upstream of the promoter.Diversification of haematopoietic stem cells to specific lineages.Behavioral regulators in the brain of neonatal chicks
P2860
Q24298841-0BF75AAD-5B79-47A4-AF84-8E9B6D38CD79Q28508595-7C721D47-F1A0-4F7E-8198-D91FDC4835D4Q33616602-5AABDDF8-C7EE-4BB9-8C6F-977CA4893433Q33703361-BECAF8BC-1CF5-459D-8FC3-218783336D8AQ33813897-D1C33292-1F55-4FFC-B19B-DE812E882D1BQ34817460-EF2E5AAB-3B72-4F88-9DA8-7C7FB8212645Q35117339-13BF50BF-B233-45D7-82DC-0CF2B06237D0Q35758842-16DB5C7B-048E-4B0A-9A53-7B3F7B5B7DF3Q36310135-BABFB1DC-F882-452C-9AE6-A85BC4A64E34Q36389520-0EC9ACF8-B721-4D37-B925-E06ADBA071D1Q36605117-CA218639-E640-4CDC-BB63-FD1BCF8E894CQ36669815-673B49ED-33CA-4BF4-9B4A-1C29B5971AB0Q36781465-7206CD54-8880-494E-9A8A-59E7BEBB2A24Q36810987-908EF234-367D-4C7E-A4AA-45A92DF2B35FQ36885829-6BC2A25E-2E85-43EB-9BCB-548FF317B79EQ36944926-F0963928-D4DB-4638-8B19-F083C5EC8C3DQ37010319-E40B689A-37AF-4F5A-89DA-22505BE68EC9Q37352714-5F96D9D9-5EE5-4154-BD70-3B5B72E4614BQ37728837-A6113CDF-8FBA-4757-A316-C58F9E5E3BC1Q38433451-82A6FC5D-8882-45A2-AF8B-1DC4EAB702D2Q38439641-1AA26492-4421-4580-9AAF-072A5AAE939DQ38457000-41E61867-8220-47AC-8A0E-8E2B30485195Q39026063-FD46238D-F9C4-4CB9-8A0C-ED937BA2447AQ41470945-919D3127-5DBF-46CB-AEEF-52AF1C00E428Q41692436-2AD8E4CA-E312-4F5C-91C7-ED660851AFDCQ42220060-2FB4F6B0-C489-428E-8251-B0C84A4EFF55Q42230758-CBB19ADC-9165-4888-81C2-937B1A2A88DBQ42935555-2DBA3D38-DE97-4E30-BAEA-F5843C1DC9E5Q43262877-7DED8DB2-9A59-4199-A53A-7DFB1DC1E9F7Q46685523-C7DC3B83-3D7C-4B9D-88B9-47F08B7529D7Q47897205-821CE2A7-DB08-45AA-8745-1040F4425EE0Q50516159-CCB8DE3D-E074-4413-A368-CEB966AF198FQ50889452-E9BD692D-3111-44AC-94CF-EB250914D60FQ50998074-42D14179-3568-4638-A060-BE4C6E5CFA63Q53458849-24395544-D9B4-4212-944D-75699A6F7917Q55034652-D48C8534-6B25-444F-97FB-43957AB38080Q58329567-8F93EE14-A24F-4510-86E1-E1F9CD6993D8
P2860
Chronic melatonin treatment and the hypothalamo-pituitary-adrenal axis in the rat: attenuation of the secretory response to stress and effects on hypothalamic neuropeptide content and release.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Chronic melatonin treatment an ...... ropeptide content and release.
@en
Chronic melatonin treatment an ...... ropeptide content and release.
@nl
type
label
Chronic melatonin treatment an ...... ropeptide content and release.
@en
Chronic melatonin treatment an ...... ropeptide content and release.
@nl
prefLabel
Chronic melatonin treatment an ...... ropeptide content and release.
@en
Chronic melatonin treatment an ...... ropeptide content and release.
@nl
P2093
P1433
P1476
Chronic melatonin treatment an ...... ropeptide content and release.
@en
P2093
O F Almeida
R Konakchieva
V K Patchev
P304
P356
10.1016/S0248-4900(98)80163-9
P577
1997-12-01T00:00:00Z